Kuros BiosurgeryKuros is a biotechnology company that develops novel biologics and biomaterial combinations for localised therapy.
Kuros products retain biologically active molecules at the site of action by incorporation into injectable matrices. These products combine the ease of injectablity with localised delivery, tunable release profiles and safety. Kuros can use natural (fibrin-based) or synthetic matrices and has a number of methodologies for the retention and release of the biologically active molecules.Kuros’ most advanced products are in the fields of tissue repair and regeneration. These products are in various stages of clinical development and have already shown clinical benefits in wound healing and bone repair. The products consist of fusion proteins of naturally occurring bioactive factors covalently incorporated into fibrin matrices. This approach attempts to mimic the body’s natural healing process: sealing a wound with fibrin which retains stimulatory growth factors that are released as repair takes place.
In addition, Kuros is developing a portfolio of proprietary products which are addressing a number of significant additional therapeutic areas including other trauma, synthetic sealant and anti-adhesion indications.
Since its creation in 2000, Kuros has raised over $40 million. The company is located in Zurich, Switzerland.
June 2, 2010
Kuros completes patient recruitment in Phase IIb study of KUR-113 in patients with tibial shaft fractures
March 15, 2010
Kuros meets primary efficacy endpoint in Phase IIb study with KUR-111
August 12, 2009
Kuros announces encouraging Phase IIa data with KUR-212 in patients with burns requiring mesh grafting
July 7, 2009
Kuros starts Phase IIb clinical trial with DUR-211 for diabetic foot ulcers
June 8, 2009
Kuros Completes patient recruitment in a phase IIb trial of KUR-111 in patients with tibal plateau fractures
September 23, 2008
Kuros and Aeris Announce Exclusive License Agreement in the Field of Lung Volume Reduction
February 22, 2007
Kuros receives orphan drug designation for a novel fusion protein for the treatment of solitary bone cysts
February 5, 2007
Kuros starts Phase II clinical trial in bone regeneration